Anke Trautwein-Schult

Arxula adeninivorans recombinant adenine deaminase and its application in the production of food with low purine content

Construction of a transgenic Arxula adeninivorans strain that produces a high concentration of adenine deaminase and investigation into the application of the enzyme in the production of food with low purine content.

Arxula adeninivorans Recombinant Urate Oxidase and Its Application in the Production of Food with Low Uric Acid Content

Hyperuricemia and its symptoms are becoming increasingly common worldwide. Elevated serum uric acid levels are caused by increased uric acid synthesis from food constituents and reduced renal excretion. Treatment in most cases involves reducing alcohol intake and consumption of meat and fish or treatment with pharmaceuticals. Another approach could be to reduce uric acid level in food, either during production or consumption. This work reports the production of recombinant urate oxidase by Arxula adeninivorans and its application to reduce uric acid in a food product. The A. adeninivorans urate oxidase amino acid sequence was found to be similar to urate oxidases from other fungi (61-65% identity). In media supplemented with adenine, hypoxanthine or uric acid, induction of the urate oxidase (AUOX) gene and intracellular accumulation of urate oxidase (Auoxp) was observed. The enzyme characteristics were analyzed from isolates of the wild-type strain A. adeninivorans LS3, as well as from those of transgenic strains expressing the AUOX gene under control of the strong constitutive TEF1 promoter or the inducible AYNI1 promoter. The enzyme showed high substrate specificity for uric acid, a broad temperature and pH range, high thermostability and the ability to reduce uric acid content in food.

Arxula adeninivorans Recombinant Guanine Deaminase and Its Application in the Production of Food with Low Purine Content

Purines of exogenous and endogenous sources are degraded to uric acid in human beings. Concentrations >6.8 mg uric acid/dl serum cause hyperuricemia and its symptoms. Pharmaceuticals and the reduction of the intake of purine-rich food are used to control uric acid levels. A novel approach to the latter proposition is the enzymatic reduction of the purine content of food by purine-degrading enzymes. Here we describe the production of recombinant guanine deaminase by the yeast Arxula adeninivorans LS3 and its application in food. In media supplemented with nitrogen sources hypoxanthine or adenine, guanine deaminase (AGDA) gene expression is induced and intracellular accumulation of guanine deaminase (Agdap) protein occurs. The characteristics of the guanine deaminase isolated from wild-type strain LS3 and a transgenic strain expressing the AGDA gene under control of the strong constitutive TEF1 promoter were determined and compared. Both enzymes were dimeric and had temperature optima of 55°C with high substrate specificity for guanine and localisation in both the cytoplasm and vacuole of yeast. The enzyme was demonstrated to reduce levels of guanine in food. A mixture of guanine deaminase and other purine degradation enzymes will allow the reduction of purines in purine-rich foods.

A novel enzymatic approach in the production of food with low purine content using Arxula adeninivorans endogenous and recombinant purine degradative enzymes

The purine degradation pathway in humans ends with uric acid, which has low water solubility. When the production of uric acid is increased either by elevated purine intake or by impaired kidney function, uric acid will accumulate in the blood (hyperuricemia). This increases the risk of gout, a disease described in humans for at least 1000 years. Many lower organisms, such as the yeast Arxula adeninivorans, possess the enzyme, urate oxidase that converts uric acid to 5-hydroxyisourate, thus preventing uric acid accumulation. We have examined the complete purine degradation pathway in A. adeninivorans and analyzed enzymes involved. Recombinant adenine deaminase, guanine deaminase, urate oxidase and endogenous xanthine oxidoreductase have been investigated as potential additives to degrade purines in the food. Here, we review the current model of the purine degradation pathway of A. adeninivorans and present an overview of proposed enzyme system with perspectives for its further development.

Front & Back Matter

Each paper must include an abstract. Abstracts should be 100–200 words. Running Title: Each paper must include a running title of no more than 80 characters. Research Articles: Original research articles should be sub-divided into the following sections: • Abstract • Introduction (concise with no sub-headings) • Results (may be sub-divided) • Discussion (results and discussion may be combined and may include sub-headings) • Experimental Procedures (should be sufficiently detailed to permit the experiments to be reproduced) • Acknowledgements • References Reviews: Review articles should be sub-divided into the following sections: • Abstract • Introduction (concise with no sub-headings) • The main text of the paper (should be divided under various headings as appropriate to the article) • Acknowledgements • References Communications: Short Communications should be 2–5 journal pages in length, should include an abstract and running title, but should not be divided into introduction, results, discussion, and experimental procedures sections. Sub-sections specifying topic are permissible. Units: Concentration to be given in g/l, etc., or molarity, M. Use the format g/ml not g ml-1. Note ml not mL. Footnotes: Avoid footnotes. When essential, they are numbered consecutively and typed at the foot of the appropriate page. Tables and Illustrations: Tables and illustrations (both numbered in Arabic numerals) should be prepared on separate sheets. Tables require a heading and figures a legend, also prepared on a separate sheet. For the reproduction of illustrations, only good drawings and original photographs can be accepted; negatives or photocopies cannot be used. Due to technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations on one block for reproduction (max. size 180  223 mm) or provide crop marks. B/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800–1200 dpi. Color Illustrations Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends. Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 800.– per page. References: Identify references [in square brackets] in the text by naming the authors and the year. 1 author: [Saier, 1994]; 2 authors: [Altschul and Karlin, 1990]; 3 and more authors: [Yen et al., 2002]. Several references listed within square brackets should be cited in an alphabetical order. Material submitted for publication but not yet accepted should be noted as ‘unpublished data’ and may not be included in the reference list. The list of references should include only those publications cited in the text. Arrange the reference list in strict alphabetical order according to the examples given below. The authors’ surnames followed by their initials should be given, and each name should be separated by a comma. Preferably, please cite all authors. For papers by the same authors, listing should be according to the year; for papers by the same authors published in the same year, use the letters a, b, c, etc. directly (no space) connected to the year. For journal abbreviations, please use the Index Medicus system. Examples (a) Papers published in periodicals: Andrade MA, Ponting C, Gibson T, Bork P: Homology-based method for identification of protein repeats using statistical significance estimates. J Mol Biol 2000;298:521–537. (b) Papers published only with DOI numbers: Theoharides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858. (c) Monographs: Matthews DE, Farewell VT: Using and Understanding Medical Statistics. Basel, Karger, 1985. (d) Edited books: Russell RRB: Genetic analysis and genetic probes for oral bacteria; in Ferguson DB (ed): Aspects of Oral Molecular Biology. Front Oral Physiol. Basel, Karger, 1991, vol 8, pp 57–76. Digital Object Identifier (DOI) S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org. Supplementary Material Supplementary material is restricted to additional data that are not necessary for the scientific integrity and conclusions of the paper. Please note that all supplementary files will undergo editorial review and should be submitted together with the original manuscript. The Editors reserve the right to limit the scope and length of the supplementary material. Supplementary material must meet production quality standards for Web publication without the need for any modification or editing. In general, supplementary files should not exceed 10 MB in size. All figures and tables should have titles and legends and all files should be supplied separately and named clearly. Acceptable files and formats are: Word or PDF files, Excel spreadsheets (only if the data cannot be converted properly to a PDF file), and video files (.mov, .avi, .mpeg). Author’s Choice Karger’s Author’s ChoiceTM service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.karger.com. The option is available for a one-time fee of CHF 3000.–, which is a permissible cost in grant allocation. More information can be found at www.karger.com/authors_choice. NIH-Funded Research The U.S. National Institutes of Health (NIH) mandates under the NIH Public Access Policy that final, peer-reviewed manuscripts appear in its digital database within 12 months of the official publication date. As a service to authors, Karger submits the final version of your article on your behalf to PubMed Central. For those selecting our premium Author’s ChoiceTM service, we will send your article immediately upon publishing, accelerating the accessibility of your work without the usual embargo. More details on NIH’s Public Access Policy is available at http://publicaccess.nih.gov/policy.htm Self-Archiving Karger permits authors to archive their pre-prints (i.e. pre-refereeing) or post-prints (i.e. final draft post-refereeing) on their personal or institution’s servers, provided the following conditions are met: Articles may not be used for commercial purposes, must be linked to the publisher’s version, and must acknowledge the publisher’s copyright. Authors selecting Karger’s Author’s ChoiceTM feature, however, are also permitted to archive the final, published version of their article, which includes copyediting and design improvements as well as citation links. Page Charges There are no page charges for papers of 6 or fewer printed pages (including tables, illustrations and references). A charge of CHF 325.– will be levied for all pages in excess of the allotted 6 printed pages. The allotted size of a paper is equal to approx. 18 manuscript pages (including tables, illustrations and references). Proofs Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations other than the correction of printer’s errors are charged to the author. Reprints The corresponding authors of all papers will receive a one-year online subscription to ‘JMMB’ free of charge. Order forms and a price list for additional reprints are sent with the galley proof. Orders submitted after the issue is printed are subject to considerably higher prices. For the rst time ever, both editions of Andreas Vesalius’ masterpiece “De Humani Corporis Fabrica” are accessible in the English language. They were critically compared and published in a modern layout transforming the Renaissance anatomical atlas for the 21st-century reader. More than 5,000 annotations cover anything from antique sources over Galenic references to the medical and cultural background of Vesalius’ time. To enable the reader and medical student to really study Vesalius’ woodcut illustrations, the images were digitally enhanced and often enlarged to feature his painstaking work of marking each pertinent anatomical part with characters. All over Vesalius’ descriptive text, the standard Latin Nomina Anatomica and Terminologia Anatomica provide the reader with the modern medical terminology. CXX + 1338 p., 340 g., in two volumes, hard cover, with slip case, 2014 12 × 17 “ / 315 × 435 mm, 16 kg / 35 lbs CHF 1,500.– / EUR 1,250.– / USD 1,650.00 Postage and handling included For details see Vesalius website ISBN 978–3–318–02246–9 Transforming Vesalius The medical revolution of the 16th century brought to life for the 21st century K I 1 32 85 A N D R E A S V E S A L I U S The Fabric of the Human Body An Annotated Translation of the 1543 and 1555 Editions of “De Humani Corporis Fabrica” by D A N I E L H . G A R R I S O N M A L C O L M H . H A S T For more information and easy ordering, please visit www.vesalius-fabrica.com